Since the introduction of digitalis into the practice of medicine by William Withering, in 1785, as a diuretic,1 numerous preparations have been tried in the search for an ideal drug for cardiac disease, one that is not only effective but also less toxic. Goodman and Gilman2 stated that a "nontoxic digitalis does not exist. A digitalis preparation which will not cause poisoning when given in excess is also one which will not exert any therapeutic effect."
Reports of the use of acetyldigitoxin have appeared in the European literature,3-6 and they have stated that it is an effective, rapidacting, well-absorbed, fairly rapidly excreted, well-tolerated digitalis preparation, but there have been relatively few American clinical trials.7 -16
Acetyldigitoxin (Acylanid) is a purified glycoside prepared first by Stoll and Kreis 17 by the enzymatic cleavage of a glucose molecule from lanatoside A, the glycoside
derived from Digitalis lanata.
GOLD MA. Acetyldigitoxin in Clinical Practice. AMA Arch Intern Med. 1957;100(2):209–213. doi:10.1001/archinte.1957.00260080035008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: